OR29-06 Flare-Ups In Patients With Fibrodysplasia Ossificans Progressiva Reduced By Garetosmab Treatment: LUMINA-1 Data

Disclosure: K.M. Dahir: Consulting Fee; Self; Alexion Pharmaceuticals, Inc., Ultragenyx, Inozyme, AM Pharma. Grant Recipient; Self; Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Inc., AstraZeneca, Ultragenyx. J. McGinniss: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahir, Kathryn M, McGinniss, Jennifer, Forleo-Neto, Eduardo, Mellis, Scott, Sanchez, Robert J, Di Rocco, Maja, Keen, Richard, Orcel, Philippe, Roux, Christian, Tabarkiewicz, Jacek, Bachiller-Corral, Javier, Cheung, Angela M, Al Mukaddam, Mona, Mohammadi, Kusha, Srinivasan, Dushyanth, Rankin, Andrew, Economides, Aris N, Gonzalez Trotter, Dinko, Kaplan, Frederick S, Eekhoff, Marelise W, Pignolo, Robert J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Bone And Mineral Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554156/
http://dx.doi.org/10.1210/jendso/bvad114.571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554156/
http://dx.doi.org/10.1210/jendso/bvad114.571

Ejemplares similares